Market Cap | 409.99M | P/E | - | EPS this Y | 64.60% | Ern Qtrly Grth | - |
Income | -29.34M | Forward P/E | 10.85 | EPS next Y | 67.10% | 50D Avg Chg | -4.00% |
Sales | 308.13M | PEG | 0.06 | EPS past 5Y | - | 200D Avg Chg | -36.00% |
Dividend | N/A | Price/Book | N/A | EPS next 5Y | -25.10% | 52W High Chg | -69.00% |
Recommedations | 2.10 | Quick Ratio | 1.02 | Shares Outstanding | 115.21M | 52W Low Chg | 21.00% |
Insider Own | 1.39% | ROA | -16.05% | Shares Float | 103.30M | Beta | 0.67 |
Inst Own | 74.70% | ROE | - | Shares Shorted/Prior | 25.09M/24.01M | Price | 4.34 |
Gross Margin | 41.51% | Profit Margin | -9.52% | Avg. Volume | 3,723,385 | Target Price | 9.50 |
Oper. Margin | -31.56% | Earnings Date | Nov 4 | Volume | 4,840,432 | Change | -3.34% |
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27. It is also developing CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody selectively targeting CCR8, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, an antibody targeting human ILT4 designed to improve anti-PD-1 clinical benefit by transforming an unfavorable TME to a more favorable TME. In addition, the company's licensed immuno-oncology programs include NZV930, an antibody designed to inhibit cluster of differentiation 73; and GSK4381562, an antibody targeting CD112R for the treatment of solid tumors. Further, it offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. It collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc., as well as Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.
HC Wainwright & Co. | Buy | Sep 16, 24 |
UBS | Neutral | Aug 16, 24 |
HC Wainwright & Co. | Buy | Aug 5, 24 |
Baird | Outperform | Jul 1, 24 |
HC Wainwright & Co. | Buy | May 24, 24 |
Truist Securities | Buy | May 13, 24 |
HC Wainwright & Co. | Buy | May 10, 24 |
HC Wainwright & Co. | Buy | Mar 20, 24 |
HC Wainwright & Co. | Buy | Mar 14, 24 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Wahlstrom Mats | Director Director | Feb 01 | Option | 1.67 | 59,988 | 100,180 | 99,988 | 02/05/24 |
Lanfear Dennis M | President & CEO President & CEO | Nov 22 | Sell | 2.02 | 223,100 | 450,662 | 731,693 | 11/24/23 |
Lanfear Dennis M | President & CEO President & CEO | Nov 22 | Option | 1.42 | 299,940 | 425,915 | 954,793 | 11/24/23 |
Vexler Vladimir | Chief Scientific Off.. Chief Scientific Officer | Mar 11 | Option | 7.14 | 102,480 | 731,707 | 167,626 | 03/11/21 |
Vexler Vladimir | Chief Scientific Off.. Chief Scientific Officer | Mar 11 | Sell | 16.25 | 114,240 | 1,856,400 | 53,386 | 03/11/21 |
Anicetti Vincent R | Chief Operating Offi.. Chief Operating Officer | Mar 09 | Option | 9.3 | 20,312 | 188,902 | 80,051 | 03/09/21 |
Anicetti Vincent R | Chief Operating Offi.. Chief Operating Officer | Mar 09 | Sell | 15.46 | 26,649 | 411,994 | 53,402 | 03/09/21 |
Viret Jean-Frederic | Chief Financial Offi.. Chief Financial Officer | Feb 03 | Option | 10.05 | 7,402 | 74,390 | 68,697 | 02/03/21 |
Viret Jean-Frederic | Chief Financial Offi.. Chief Financial Officer | Feb 03 | Sell | 21.55 | 7,402 | 159,513 | 61,295 | 02/03/21 |
Viret Jean-Frederic | Chief Financial Offi.. Chief Financial Officer | Jan 27 | Option | 10.05 | 40,000 | 402,000 | 107,439 | 01/27/21 |
Viret Jean-Frederic | Chief Financial Offi.. Chief Financial Officer | Jan 27 | Sell | 19.55 | 46,144 | 902,115 | 61,295 | 01/27/21 |
Anicetti Vincent R | Chief Operating Offi.. Chief Operating Officer | Dec 09 | Option | 12.54 | 8,791 | 110,239 | 41,360 | 12/09/20 |
Anicetti Vincent R | Chief Operating Offi.. Chief Operating Officer | Dec 09 | Sell | 18.42 | 8,791 | 161,930 | 32,569 | 12/09/20 |
Anicetti Vincent R | Chief Operating Offi.. Chief Operating Officer | Nov 19 | Option | 7.6 | 6,783 | 51,551 | 36,852 | 11/19/20 |
Anicetti Vincent R | Chief Operating Offi.. Chief Operating Officer | Nov 19 | Sell | 17.71 | 22,770 | 403,257 | 32,569 | 11/19/20 |